Cabaletta Bio (CABA) Reports Q4 Results, Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. AXP
9. TMUS
10. SPY

Go back to Cabaletta Bio (CABA) Reports Q4 Results, Provides Business Update

Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

March 17, 2022 7:00 AM EDT

DesCAARTes trial progressing in cohort A5 with presentation of DSG3-CAART clinical and translational data from cohorts A3 and A4 and 28-day safety data for cohort A5 expected at upcoming scientific meetings in mid-2022

MuSK-CAART Investigational New Drug (IND) application cleared and Fast Track Designation granted by the U.S. Food and Drug Administration (FDA); planning to initiate first-in-human trial in 2022

Ended 2021 with $122.2 million in cash on hand to fund operations through 3Q 2023

PHILADELPHIA, March 17, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a... More